表紙:未分化リンパ腫キナーゼ阻害剤の世界市場-成長、将来展望、競合分析(2022年~2030年)
市場調査レポート
商品コード
1149061

未分化リンパ腫キナーゼ阻害剤の世界市場-成長、将来展望、競合分析(2022年~2030年)

Anaplastic Lymphoma Kinase Inhibitors Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.36円
未分化リンパ腫キナーゼ阻害剤の世界市場-成長、将来展望、競合分析(2022年~2030年)
出版日: 2022年08月04日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の未分化リンパ腫キナーゼ阻害剤の市場規模は、2020年の21億3,080万米ドルから、2030年には168億8,940万米ドルに達し、2022年から2030年までのCAGRは21.2%と予測されています。優れた薬力学的および薬物動態学的特性、肺がん罹患率の上昇、安価な償還シナリオは、未分化リンパ腫キナーゼ阻害剤市場の成長を牽引しています。

当レポートでは、世界の未分化リンパ腫キナーゼ阻害剤市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-2次調査
    • フェーズⅡ-1次調査
    • フェーズⅢ-専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット:世界の未分化リンパ腫キナーゼ阻害剤市場
  • 世界の未分化リンパ腫キナーゼ阻害剤市場(100万米ドル)(2021年):分子別
  • 世界の未分化リンパ腫キナーゼ阻害剤市場(100万米ドル):地域別
  • COVID-19の影響
  • 魅力的な投資提案(2021年):地域別
  • 競合分析
    • 主要な未分化リンパ腫キナーゼ阻害剤市場ベンダーの市場ポジショニング
    • 未分化リンパ腫キナーゼ阻害剤市場ベンダーが採用する戦略
    • 主要な業界戦略

第3章 未分化リンパ腫キナーゼ阻害剤市場:ビジネス展望と市場力学

  • イントロダクション
  • 世界の未分化リンパ腫キナーゼ阻害剤の市場金額(100万米ドル)(2020年~2030年)
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年):分子別

  • 市場概要
  • 成長と収益分析:2021年と2030年の比較
  • 市場セグメンテーション
    • クリゾチニブ
    • セリチニブ
    • アレクチニブ塩酸塩

第5章 北米の未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年)

第6章 英国および欧州連合の未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年)

第7章 アジア太平洋の未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年)

第8章 ラテンアメリカの未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年)

第9章 中東およびアフリカの未分化リンパ腫キナーゼ阻害剤市場、米ドル(100万)(2020年~2030年)

第10章 企業プロファイル

  • Betta Pharmaceuticals Co., Ltd.
  • Criterium, Inc.
  • F. Hoffman-La Roche Ltd.
  • Helsinn Therapeutics
  • Novartis AG
  • Oncoethix GmbH
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • Xcovery Holding Company, LLC
  • Tesaro, Inc.
図表

List of Tables

  • TABLE 1 Global Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)
  • TABLE 2 North America Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)
  • TABLE 5 Latin America Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market By Molecule, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Anaplastic Lymphoma Kinase Inhibitors Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anaplastic Lymphoma Kinase Inhibitors Market: Quality Assurance
  • FIG. 5 Global Anaplastic Lymphoma Kinase Inhibitors Market, By Molecule, 2021
  • FIG. 6 Global Anaplastic Lymphoma Kinase Inhibitors Market, By Geography, 2021
  • FIG. 7 Global Anaplastic Lymphoma Kinase Inhibitors Market, By Molecule, 2021 Vs 2030, %
  • FIG. 8 U.S. Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 15 France Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 17 China Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 19 India Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market (US$ Million), 2020 - 2030
目次
Product Code: 138755-08-22

Industry Outlook

The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 2,130.8 Mn in 2020 to 16,889.4 Mn by 2030 keen to demonstrate exuberating growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2022 to 2030. Lung cancer is the second most occurring type of cancer in both men and women population worldwide. Increased consumption of tobacco, unhealthy lifestyle and stress are the major risk factor responsible for the occurrence of lung cancer. A strong drug pipeline of second and third-generation ALK inhibitors being currently studied in various stages of clinical trials are being developed specifically for the treatment of non small cell lung cancer (NSCLC).

"Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first generation ALK inhibitors"

Non small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of the NSCLC is difficult and its initial screening is rather poor which significantly increases the requirement for development of targeted drug therapy for its treatment. FDA has approved only 2 drugs specifically for the treatment of NSCLC In the present scenario first generation ALK inhibitor Crizotinib is spearheading the molecule segment for anaplastic lymphoma kinase inhibitors market. It is basically an aminopyridine and piperidine derivative which selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth. Alectinib hydrochloride is another first line ALK inhibitor which effectively inhibits wild type ALK point mutant variants and disrupts the tumor cell growth associated with advanced stage NSCLC. Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first generation ALK inhibitors.

"Rising prevalence of lung cancer and affordable reimbursement scenario together drive the market growth in North America region"

Representing a share of 36.2% North America is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors market. According to the research findings of American Society of Clinical Oncology (ASCO), in 2021, approximately 228,150 U.S. citizens have been reported to be suffering with lung cancer with a high prevalence rate in African American people. Affordable reimbursement scenario pertaining to the treatment of non small cell lung cancer drives the market growth ALK inhibitors in North America region. Europe is in the second place with 29.8% market share primarily due to huge prevalence rate of lung cancer in the European Union which is 54 per 100,000 people as brought forward by the 2020 statistical report of European Commission. Supportive regulatory environment provided by the European Medical Agency to expedite the clinical trials pertaining to second and third generation anaplastic lymphoma kinase inhibitors for the treatment of non small cell lung cancer (NSCLC). Asia Pacific presently accounts for 15.5% market share and is keen to register outstanding growth during the forecast period on account of significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.

Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitors market are Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC and Tesaro, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anaplastic Lymphoma Kinase Inhibitors market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anaplastic Lymphoma Kinase Inhibitors market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Molecule

Crizotinib

Ceritinib

Alectinib Hydrochloride

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Anaplastic Lymphoma Kinase Inhibitors market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anaplastic Lymphoma Kinase Inhibitors market?

Which is the largest regional market for Anaplastic Lymphoma Kinase Inhibitors market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anaplastic Lymphoma Kinase Inhibitors market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anaplastic Lymphoma Kinase Inhibitors market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anaplastic Lymphoma Kinase Inhibitors Market
  • 2.2. Global Anaplastic Lymphoma Kinase Inhibitors Market, By Molecule, 2021 (US$ Million)
  • 2.3. Global Anaplastic Lymphoma Kinase Inhibitors Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Anaplastic Lymphoma Kinase Inhibitors Market Vendors
    • 2.6.2. Strategies Adopted by Anaplastic Lymphoma Kinase Inhibitors Market Vendors
    • 2.6.3. Key Industry Strategies

3. Anaplastic Lymphoma Kinase Inhibitors Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Anaplastic Lymphoma Kinase Inhibitors Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Crizotinib
    • 4.3.2. Ceritinib
    • 4.3.3. Alectinib Hydrochloride

5. North America Anaplastic Lymphoma Kinase Inhibitors Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)
  • 5.3.Anaplastic Lymphoma Kinase Inhibitors Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Anaplastic Lymphoma Kinase Inhibitors Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)
  • 6.3.Anaplastic Lymphoma Kinase Inhibitors Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)
  • 7.3.Anaplastic Lymphoma Kinase Inhibitors Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Anaplastic Lymphoma Kinase Inhibitors Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)
  • 8.3.Anaplastic Lymphoma Kinase Inhibitors Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anaplastic Lymphoma Kinase Inhibitors Market: By Molecule, 2020-2030, USD (Million)
  • 9.3.Anaplastic Lymphoma Kinase Inhibitors Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Betta Pharmaceuticals Co., Ltd.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Criterium, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. F. Hoffman-La Roche Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Helsinn Therapeutics
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Novartis AG
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Oncoethix GmbH
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Pfizer, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Takeda Pharmaceutical Co., Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Xcovery Holding Company, LLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Tesaro, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives